Testing effectiveness (Phase 2)UnknownNCT05390840
What this trial is testing
Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)
Who this might be right for
Age-Related Macular Degeneration
Theratocular Biotek Co. 36